MAY 03, 2018 01:48 AM PDT

Treating Migraines with Less Side-Effects

WRITTEN BY: Nouran Amin

According to a 2013 Global Burden of Disease Study and the World Health Organization (WHO), migraine makes the list as the sixth highest cause worldwide for years lost due to disability.

Now, scientists have stumbled upon a side-effect free treatment option for chronic migraines. These side-effects that are usually accompanied with conventional treatments include fatigue, racing heartbeat, or nausea.

The discovered drug is erenumab which works against migraines to inhibit pain signals by targeting a receptor for calcitonin gene-related peptide (CGRP). According to the American Academy of Neurology, CGRP is responsible for the pain trsamiiosn. With erenumab, the drug works to inhint the nerves to which CGRP peptide binds, ebentiaull blocking the pain.

To test the effectiveness of the drug, investigators examined 246 people who are considered “more difficult to treat” noted by study author Uwe Reuter in a news release. The participants received injections of either 140 milligrams of erenumab or a placebo once every month for a total of three months.

“Our results show that people who thought their migraines were difficult to prevent may actually have hope of finding pain relief,” explains Uwe Reuter said, “More research is now needed to understand who is most likely to benefit from this new treatment.” However, one disadvantage from this study was that researchers evaluated patients over a three-month period.

Current treatment options for migraines include OTC counter NSAIDs or dedicated triptans. These treatment options come with their own side effects such as drowsiness, dizziness or slow-thinking. “There’s no current dedicated migraine prevention medication,” says Dr. Michael R. Silver, an assistant professor in neurology at Emory University. “We borrow from other fields and use mostly anti-seizure medicines, blood pressure medicines or anti-depressants for migraine prevention.”

However, erenumabs provide promising treatment. “We’ve known CGRP have been involved in migraines for years and now, we’re finally coming out with medicines to address what is likely the root cause of migraine pain.”

Although erenumab is currently up for approval by the FDA, one downside might be the cost of having this treatment. Regardless, Dr. Silver believes that “this will hopefully usher in the new era of migraine treatment”.

Sources: American Academy of Neurology

 

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
JUL 24, 2018
Drug Discovery
JUL 24, 2018
An Inhibitory Compound 'ITI-214' Shows Promising Effects for Heart Failure Patients
According to early studies on animals at John Hopkins School of Medicine, a current drug examined in clinical trials to treat symptoms of Parkinson's d...
AUG 21, 2018
Drug Discovery
AUG 21, 2018
Genetic Regulators of Regeneration Bring Hope for Drug Discovery
Portions of DNA that do not seem to have a function are referred to as “junk”. Now, according to a study published in Regenerative Medicine, re...
AUG 28, 2018
Drug Discovery
AUG 28, 2018
Combination Therapy for Advanced Melonoma
According to a research study led by UCLA, a bacteria-like agent used in combination with an immunotherapeutic drug may help patients survive longer with a...
SEP 18, 2018
Drug Discovery
SEP 18, 2018
Clinical-Grade Drugs for Bone Diseases
According to a study published in Journal of Gerontology: Biological Sciences, a small molecule was discovered to play a role in bone formation, ultimately...
SEP 23, 2018
Cell & Molecular Biology
SEP 23, 2018
Insulin may be a new Colitis Treatment
Insulin is a necessary medicine for diabetics, but new work shows that insulin may also be used to treat chronic bowel inflammation....
OCT 02, 2018
Drug Discovery
OCT 02, 2018
Mycobacterial Lung Disease, FDA Approves New Drug
New drug seeking to treat antibiotic-resistant lung disease has just been approved by the U.S. Food and Drug Administration. The drug is called ‘Arik...
Loading Comments...